New $461M venture fund for RA RA Capital raised $461 million for its Nexus Fund II, its second venture fund that like 2019’s $300 million Nexus I Fund will invest in private companies backed by the...

A proposed regulation from the Department of Treasury could change what triggers CFIUS review of foreign investment in U.S.-based “critical technology” companies. The rule could increase mandatory filings for companies with investors from countries subject...

FDA center directors Janet Woodcock and Peter Marks will not participate in reviews of COVID-19 products after taking on leadership roles in Operation Warp Speed, FDA Commissioner Stephen Hahn announced in an email to agency...

Fibrosis company Avalyn raises $35.5M series B Seattle’s Avalyn Pharma Inc. closed a $35.5 million B round, adding to its $62 million series A in 2017. The round was led by Norwest Venture Partners with...

Emerging from stealth Monday with a $50 million A round, Quench Bio is targeting the nexus of inflammatory cell death. RA Capital led the round with participation from new investor AbbVie Ventures. Atlas Venture and...

Israeli fund group Accelmed has launched a $100 million fund to invest in health-tech companies it views as attractive takeover targets. Accelmed Ventures II will focus on prerevenue med-tech and digital health companies in Israel...

RA launches $300M VC fund RA Capital raised $300 million for its first close-ended venture fund, dubbed Nexus, which will invest in private companies backed by the firm's main fund, RA Capital Healthcare Fund L.P....

Bright Angel is tackling antifungal resistance at its root with inhibitors of Hsp90 and other stress response factors, unlike competitors that are developing compounds against known or new pathways where resistance can still emerge. Resistance...

Unfazed by the shaky start of the Hong Kong stock exchange’s new biotech chapter, HKEX CEO Charles Li thinks its position at the nexus of East and West will underpin its long-term success. With more...

A consortium of companies and regulators could trigger a step change in how industry uses in silico toxicology to evaluate drug impurities and reduce the list of wet experiments required for regulatory submissions. So far,...